Exosomal microRNAs as Early Transition Biomarkers from Recurrent-Remissive to Secondary Progressive Multiple...

Area of Science:

• Neuroimmunology
• Molecular Biology

Background:

• Multiple sclerosis (MS) is a chronic, immune-mediated neurological disease impacting young adults.
• Relapsing-remitting MS (RRMS) often progresses to secondary progressive MS (SPMS), a transition difficult to predict clinically.
• Current diagnosis of SPMS relies on accumulated disability, often after significant disease progression.

Purpose of the Study:

• To emphasize the need for molecular biomarkers to identify the RRMS to SPMS transition phase.
• To facilitate earlier intervention with high-efficacy treatments.
• To potentially halt or slow clinical disease progression.

Main Methods:

• Review of existing research on microRNAs (miRNAs) in multiple sclerosis.
• Focus on specific miRNAs, such as miR-155, implicated in MS pathogenesis.
• Analysis of miRNA roles in blood-brain barrier integrity and neurodegeneration.

Main Results:

• MicroRNAs, particularly miR-155, show potential as early biomarkers for MS progression.
• miR-155 is linked to key pathological features including blood-brain barrier dysfunction and neurodegeneration.
• This miRNA may serve as an indicator for the transition from RRMS to SPMS.

Conclusions:

• Identifying a reliable molecular biomarker is essential for predicting MS progression.
• Early detection of the RRMS to SPMS transition can lead to timely and effective therapeutic strategies.
• Further research into miRNAs like miR-155 could revolutionize MS management.